Medmix : Half-Year 2023 Results Presentation

Half-year results 2023

Girts Cimermans CEO, Jennifer Dean CFO

July 20, 2023

Providing innovative solutions to help people

live healthier and more confident lives

Disclaimer and other important notes

This presentation contains forward-looking statements that are based on management's current assumptions and expectations concerning future developments, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, which therefore contain certain risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made in this presentation. These risks and other factors include, among others, general economic and geopolitical conditions, foreign exchange fluctuations, competitive product and pricing pressures, the effect of a pandemic or epidemic, a cyber event, a natural disaster or other force majeure, as well as regulatory developments and changes in tax regimes.

Alternative Performance Measures (APM)

All bridges from reported figures to APM can be found in the financial review of medmix' half-year report 2023 and all definitions of APM can be found in the APM section of medmix' annual report 2022.

2

medmix CONFIDENTIAL

Business Review

Girts Cimermans CEO

medmix CONFIDENTIAL

Half-year 2023 highlights

Solid recovery underway

	Adjusted
Group	EBITDA
49.7
Revenues
248.1	-17% vs. H1 2022
+1% vs. H1 2022	+10% vs. H2 2022
+12% vs. H2 2022

Healthcare

Revenues

89.2

-11% vs. H1 2022 +10% vs. H2 2022

	Industry
	Market Segment
Consumer &	New Plant

All amounts in CHF millions All profit growth rates nominal All revenue growth rates organic (i.e., excluding M&A & forex)

Business Area

Gross Profit

108.6

-10% vs. H1 2022 +11% vs. H2 2022

Industrial Revenues
158.9	Production trials since April
PL assets now in ES
First customer
+9% vs. H1 2022	deliveries
+14% vs. H2 2022

medmix CONFIDENTIAL

4

Revenues and growth by market segment

Healthcare BA

Consumer & Industrial BA ("C&I")

Dental	Drug	Industry	Beauty
Surgery
	Delivery

• 53.7 -24%( +1% vs. H2 2022 )

• Tough H1 2022 comps
• Customer overstocking in 2021 and H1 2022
• Destocking in H1 2023 and likely into H2 2023

	26.9	+18%	8.6	+28%
	( +21% vs. H2 2022 )	( +42% vs. H2 2022 )
•	Strong product and	• Conversion of tissue
•	project pipeline	banks to medmix
PiccoJectTM a success	products

	72.7	-8%		86.3	+30%
	( +6% vs. H2 2022 )		( +21% vs. H2 2022 )
•	Revenues still limited by	•	Customer product
•	relocation of production		launches after lifting of
Recovery vs. H2 2022		Covid restrictions
•	Capacity to be increased	•	Incremental MBA sales
	during H2 2023

Revenues are in CHF million, growth rates are organic (i.e., excluding M&A & forex)

medmix CONFIDENTIAL

5